Durvalumab vs Niraparib Tosylate Monohydrate

Durvalumab vs Niraparib Tosylate Monohydrate: Overview

This comparison examines the pharmacological differences between Durvalumab and Niraparib Tosylate Monohydrate.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Durvalumab — 17 days.

Chemical Properties

Type: Durvalumab — Antibody; Niraparib Tosylate Monohydrate — Small molecule.